Skip to main content
Premium Trial:

Request an Annual Quote

Bucking the Trend

This may mess up your "merger madness" bracket (kind of like Villanova is doing for the basketball brackets): Eli Lilly is not interested in a merger with Bristol-Myers Squibb, reports the Financial Times. CEO John Lechleiter told the FT that he'd rather "work to boost his company's internal development of experimental medicines alongside selective smaller-scale deals."

Drawing from S4 filings Pfizer made with the SEC, The Wall Street Journal Health Blog reports that an unnamed drug company "threatened to throw a monkey wrench" into the Pfizer/Wyeth deal. "Company X" tried to get financing from Morgan Stanley on December 16th, but by the 24th, X was out of the game. The Pfizer-Wyeth deal was announced about a month later.

The Scan

Not Yet a Permanent One

NPR says the lack of a permanent Food and Drug Administration commissioner has "flummoxed" public health officials.

Unfair Targeting

Technology Review writes that a new report says the US has been unfairly targeting Chinese and Chinese-American individuals in economic espionage cases.

Limited Rapid Testing

The New York Times wonders why rapid tests for COVID-19 are not widely available in the US.

Genome Research Papers on IPAFinder, Structural Variant Expression Effects, Single-Cell RNA-Seq Markers

In Genome Research this week: IPAFinder method to detect intronic polyadenylation, influence of structural variants on gene expression, and more.